A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1203-1213

  McDermott, David F ^b   Trehu, Elizabeth G ^b   Mier, James W ^b   Sorce, Damian ^b   Rand, William ^b   Ronayne, Lucie ^b   Kappler, Kerry ^b   Clancy, Marguerite ^b   Klempner, Mark ^b   Atkins, Michael B ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; MELANOMA; METASTASIS; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VITILIGO;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CELL ADHESION MOLECULES; CHO CELLS; CRICETINAE; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEUTROPHILS; NITRATES; RECEPTORS, INTERLEUKIN-1;

EID: 15644364246     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkinson, D. R., Fisher, R. I., Rayner, A. A., Paietta, E., Margolin, K. A., Weiss, G. R., Mier, J. W., Sznol, M., Gaynor, E. R., and Bar, M. H. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol., 8: 1630-1636, 1990.
2. Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H., Atkins, M. B., and Hawkins, M. J. Interleukin-2 therapy in patients with metastatic malignant melanoma: a Phase II study. J. Clin. Oncol., 8: 1650-1656, 1990.
3. Fisher, R. I., Coltman, C. A., Jr., Doroshow, J. H., Rayner, A. A., Hawkins, M. J., Mier, J. W., Wiernik, P., McMannis, J. D., Weiss, G. R., Margolin, K. A., Gemlo, B. T., Hoth, D. F., Parkinson, D. R., and Paietta, E. Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells: a Phase II clinical trial. Ann. Intern. Med., 108: 518-523, 1988.
4. Bar, M. H., Sznol, M., Atkins, M. B., Ciobanu, N., Micetich, K. C., Boldt, D. H., Margolin, K. A., Aronson, F. R., Rayner, A. A., Hawkins, M. J., Mier, J. W., Paietta, E., Fisher, R. I., Weiss, G. R., and Doroshow, J. H. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J. Clin. Oncol., 8: 1138-1147, 1990.
5. Atkins, M. B., Sparano, J., Fisher, R. I., Weiss, G. R., Margolin, K. A., Fink, K. I., Rubinstein, L., Louie, A., Mier, J. W., Gulcap, R. Sosman, J. A., Boldt, D. H., Doroshow, J. H., Aronson, F. R., and Sznol, M. Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon α-2b in advanced renal cell carcinoma. J. Clin. Oncol., , 11: 661-670, 1993.
6. Dutcher, J. P., Creekmore, S., Weiss, G. R., Margolin, K., Markowitz, A. B., Roper, M., Parkinson, D., Ciobanu, N., Fisher, R. I., Boldt, D. H., Doroshow, J. H., Rayner, A. A., Hawkins, M., and Atkins, M. A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J. Clin. Oncol., 7: 477-485, 1989.
7. Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., and Schwarz, S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med., 161: 1169-1188, 1985.
8. Bradley, E. C., Louie, A. C., Paradise, C. M., Carlin, D. A., Bleyl, K. L., Groves, E. S., and Rudolph, A. R. Antitumor response in patients with metastatic renal cell carcinoma is dependent upon regimen intensity. Proc. ASCO, 8: 133, 1989.
9. Parkinson, D. R. Interleukin-2 in cancer therapy. Semin. Oncol., 15 (Suppl.6): 10-26, 1988.
10. Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., Roper, M., Parkinson, D. R., Wiernik, P. H., Creekmore, S. P., and Boldt, D. H. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
11. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Results of treatment of 255 patients with metastatic renal cell cardinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696, 1995.
12. Numerof, R. P., Aronson, F. R., and Mier, J. W. IL-2 stimulates the production of IL-1 α and IL-1 β by human peripheral blood mononuclear cells. J. Immunol., 141: 4250-4257, 1988.
13. Numerof, R. P., Kotik, A. N., Dinarello, C. A., and Mier, J. W. Pro-interleukin-1 β production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2. Cell. Immunol., 130: 118-128, 1990.
14. Mier, J. W., Vachino, G., van der Meer, J. W., Numerof, R. P., Adams, S., Cannon, J. G., Bernheim, H. A., Atkins, M. B., Parkinson, D. R., and Dinarello, C. A. Induction of circulating tumor necrosis factor (TNF α) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol., 8: 426-436, 1988.
15. Nedwin, G. E., Svedersky, L. P., Bringman, T. S., Paladino, M. A., Jr., and Goeddel, D. V. Effect of interleukin-2, interferon-γ, and mitogens on the production of tumor necrosis factors α and β. J. Immunol., 135: 2492-2497, 1985.
16. Hibbs, J. B., Westenfelder, C., Taintor, R. Vavrin, Z., Kablitz, C., Baranowski, R. L., Ward, J. H., Menlove, R. L., McMurry, M. P., Kushner, J. P., and Samlowski, W. E. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest., 89: 867-877, 1992.
17. Cox, G. W., Melillo, G., Chattopadhyay, U., Mullet, D., Fertel, R. H., and Varesio, L. Tumor necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol., 149: 3290-3296, 1992.
18. Mier, J., Vachino, G., Numerof, R., and Atkins, M. Mechanisms of Action, Therapeutic Applications of Biologicals in Cancer, and Immune Deficiency. In: J. Groopman, C. Evans, and D. Golde (eds.), UCLA Symposia on Molecular, and Cellular Biology, New Series, Vol. 100, No. 53. New York: Alan R. Liss, Inc., 1989.
19. Mier, J. W., Vachino, G., Klempner, M. S., Aronson, F. R., Noring, R., Smith, S., Brandon, E. P., Laird, W., and Atkins, M. B. Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotactic defect and differential suppression of interleukin-2 associated side effects. Blood, 76: 1933-1940, 1990.
20. Fraker, D. L., Langstein, H. N., and Norton, J. A. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J. Exp. Med., 170: 1015-1020, 1989.
21. Fraker, D. L., Thorn, A. K., Doherty, G. M., Langstein, H. N., Buresh, C. M., and Norton, J. A. Tumor necrosis factor mediates the survival benefit of interleukin-2 in a murine pulmonary metastates model. Surg. Oncol., 1: 1-9, 1992.
22. Trehu, E. G., Mier, J. W., Shapiro, L., Epstein, M., Klempner, M., Dinarello, C. A., Kappler, K., Ronayne, L., Rand, W., and Atkins, M. B. A Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 immunoglobulin G chimera (TNFR:Fc). Clin. Cancer Res., 2: 1341-1351, 1996.
23. Du Bois, J., Trehu, E. G., Mier, J. W., Shapiro, L. Epstein, M., Klempner, M., Dinarello, C., Kappler, K., Ronayne, L., and Atkins, M. B. Randomized placebo-controlled clinical trial of high-dose interleukin-2 (IL-2) in combination with the soluble TNF receptor IgG chimera (TNFR:Fc). J. Clin. Oncol., 15: 1052-1062, 1997.
24. Dower, S. K., Wignall, J. M., Scholley, K., McMahan, C. J., Jackson, J. L., Prickett, K. S., Lupton, S., Cosman, D., and Sims, J. E. Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J. Immunol., 142: 4314-4320, 1989.
25. Preas, H. L., II, Reda, D., Tropea, M., Vandivier, W., Banks, S. M., Agosti, J. M., and Suffredini, A. F. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses of endotoxin. Blood, 88: 2465-2472, 1996.
26. van der Meer, J. W., Endres, S., Lonneman, G., Cannon, J. G., Ikejima, T., Okusawa, S., Gelfand, J. A., and Dinarello, C. A. Concentrations of immunoreactive tumor necrosis factor-α produced by human mononuclear cells in vitro. J. Leukocyte Biol., 43: 216-223, 1988.
27. Poutsiaka, D. D., Clark, B. D., Vannier, E., and Dinarello, C. A. Production of interleukin-1 receptor antagonist and interleukin-1B by peripheral blood mononuclear cells is differentially regulated. Blood, 78: 1275-1281, 1991.
28. Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S. C., and Dinarello, C. A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood, 75: 40-47, 1990.
29. Porat, R., Poutsiaka, D. D., Miller, L. C., Granowitz, E. V., and Dinarello, C. A. Interleukin-1 (IL-I) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J., 6: 2482-2486, 1992.
30. Hogan, M. M., and Vogel, S. N. Measurement of tumor necrosis factor α and β. In: J. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology, pp. 6.10.1-6.10.5. New York: John Wiley & Sons, Inc., 1994.
31. Bartholomew, B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem. Toxicol., 22: 541-543, 1984.
32. Granger, D. L., Hibbs, J. B., Perfect, J. R., and Durack, D. T. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest., 85: 264-273, 1990.
33. Klempner, M. S., Noring, R., Mier, J. W., and Atkins, M. B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med., 322: 959-965, 1990.
34. DeLellis, R. A., Stemberger, L. A., Mann, R. B., Banks, P. M., and Nakane, P. K. Immunoperoxidase techniques in diagnostic pathology: report of a workshop sponsored by the National Cancer Institute. Am. J. Clin. Pathol., 71: 483-488, 1979.
35. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
36. Atkins, M. B., Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M., and Kaplan, M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med., 318: 1557-1563, 1988.
37. Dutcher, J., Atkins, M., Fisher, R., Weiss, G., Margolin, K., Aronson, F., Lotze, M., and Gordon, M. IL-2 based therapy in metastatic renal cell cancer: Cytokine Working Group experience. ASCO Abstr., 16: 1166, 1996.
38. Royal, R. E., Steinberg, S. M., and White, D. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J. Sci. Am., 6: 91-98, 1996.
39. Faherty, D. A., Claudy, V., Plocinski, J. M., Kaffka, K., Kilian, P., Thompson, R. C., and Benjamin, W. R. Failure of IL-1 receptor antogonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J. Immunol., 148: 766-771.